Company
Technology
Team
Board of Directors
Management
Extended Management
Partners & Advisors
Preclinical Research
Clinical Research
Strategic Investment
Investors
News
Contact
News
Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer
9 August 2022
READ MORE
Bilanz: Important Milestone
28 June 2022
READ MORE
Finanz und Wirtschaft: Doubts about the market for corona boosters
24 June 2022
READ MORE
RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models
9 June 2022
READ MORE
RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships
16 March 2022
READ MORE
Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science
12 November 2021
READ MORE
Swiss biotech companies in fight against the coronavirus
18 April 2022
READ MORE
Volker Thiel: “There can be a summer wave”
28 March 2022
READ MORE
Swiss vaccine candidates enter clinical trial phase
28 March 2022
READ MORE
New Swiss COVID-19 vaccination as a nasal spray
28 March 2022
READ MORE
Serbian state institutions and media representatives have been reporting on the recipient of the Nikola Tesla Award, Dr. Vladimir Cmiljanovic
18 November 2021
READ MORE
CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to RTS about the development of a second-generation SARS-CoV-2 vaccine
30 September 2021
READ MORE
L’Avenir: “Two new vaccines are expected in late 2021”
19 August 2021
READ MORE
Le Temps is reporting about CHF 7.2 million of seed funding raised for the development of RocketVax’s SARS-CoV-2 vaccine
6 August 2021
READ MORE
RocketVax successfully raises CHF 7.2 million of seed funding
3 August 2021
READ MORE
LOAD MORE NEWS